Biocon Ltd. — Regulatory Filings 2020

May 12, 2020

==> picture [132 x 52] intentionally omitted <==

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417

www.biocon.com

May 12, 2020

To	To
The Manager	The Manager,
BSE Limited	National Stock Exchange of India Limited
Department of Corporate Services	Corporate Communication Department
Phiroze Jeejeebhoy Towers,	Exchange Plaza, Bandra Kurla Complex
Dalal Street,Mumbai – 400 001	Mumbai – 400 050
Scrip Code- 532523	Scrip Symbol- Biocon

Dear Sir/Madam,

Subject: Biocon Biologics Drug Substance Facilities in Bengaluru Receive EU GMP Certification.

Please find below the “Company Statement” on the subject matter.

“This is to inform you that Biocon Biologics India Ltd., a subsidiary of Biocon Ltd. has received the Certificate of GMP compliance from EMA represented by the competent authority of Germany for its Biologics Drug Substance (DS), facilities at 20[th] KM, Hosur Road, Bengaluru.

These facilities are used for the manufacture of drug substance of Pegfilgrastim and Recombinant Human Insulin and manufacturing related activities for Insulin Glargine and Insulin Aspart and were inspected by the regulatory agency between January 20 and 23, 2020.

This certification will enable us to continue addressing the growing needs of patients in the EU markets and enhance access to our high quality biosimilars. We remain committed to global standards of quality and compliance." - Company Spokesperson

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

==> picture [97 x 36] intentionally omitted <==

==> picture [77 x 81] intentionally omitted <==

---

Mayank Verma Company Secretary and Compliance Officer